Emerging evidence suggests that GLP-1 and dual GLP-1/GIP receptor agonists exert modulatory effects on both the volume and functional properties of epicardial adipose tissue (EAT), thereby potentially mitigating the risk of obesity-related cardiomyopathy. The gene discussed is GLP1R; the disease is cardiomyopathy.